Adelaide Cancer Centre

Kurralta Park SA 5037

0 studies enrolling now · 3 studies all time

What they study most

Indolent Non-Hodgkin's Lymphomas, UC (Urothelial Cancer)

Studies at this site

• Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) — Completed
• Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma — Completed
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas — Stopped early